

Systemic Therapy Update



BC Cancer Agency

CARE + RESEARCH

An agency of the Provincial Health Services Authority

June 2017
Volume 20, No. 6

For Health Professionals Who Care For Cancer Patients

Inside This Issue:

- **Editor's Choice** – **New Programs:** Epirubicin, Oxaliplatin and Fluorouracil or Capecitabine for Gastric Cancer
- **Benefit Drug List** – **New:** GIGAVEOCAP, GIGAVEOF
- **Cancer Drug Manual** – **Revised:** Capecitabine, Dabrafenib, Trametinib, Vemurafenib; Changes in Editorial Board: New Team and Board Members
- **List of New and Revised Protocols, Provincial Pre-Printed Orders and Patient Handouts:** **New:** GIGAVEOCAP, GIGAVEOF; **Revised:** BRAVGEMT, UGIAJRALOX, GIAVPG, GIGAJCPRT, GIPAJGCAP, GIPAJGEM, GIPGEM, GIPGEMABR, GOCXCATB, ULYBRENTUX, LYCVP, USMAVFIPI, USMAVIPI, USMAVNIV SMAVTMZ, SMCCNU, SMTAM
- **Website Resources and Contact Information**

EDITOR'S CHOICE

NEW PROGRAMS

Effective 1 June 2017, the BCCA Provincial Systemic Therapy Program has approved the following program.

Gastrointestinal:

Epirubicin, Oxaliplatin and Capecitabine (GIGAVEOCAP) or Fluorouracil (GIGAVEOF) for Metastatic or Locally Advanced Gastric or Esophagogastric Cancer – Patients with advanced gastric, esophagogastric or esophageal adenocarcinoma are currently treated with epirubicin, cisplatin and fluorouracil (or capecitabine). In a phase III trial, substitution of cisplatin with oxaliplatin in the combination regimen was shown to be similar (non-inferior) in overall survival. The oxaliplatin-based regimen was associated with a lower risk of grade 3 or 4 neutropenia, alopecia, renal toxicity, and thromboembolism, but with slightly higher incidences of grade 3 or 4 diarrhea and neuropathy.

Reference:

Cunningham D, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36-46.

BENEFIT DRUG LIST

NEW PROGRAMS

Effective 1 June 2017, the following BCCA treatment programs have been added to the BCCA [Benefit Drug List](#):

Protocol Title	Protocol Code	Benefit Status
Palliative Therapy for Metastatic or Locally Advanced Gastric or Esophagogastric Cancer Using <i>Epirubicin</i> , <i>Oxaliplatin</i> and <i>Capecitabine</i>	GIGAVEOCAP	Class I
Palliative Therapy for Metastatic or Locally Advanced Gastric or Esophagogastric Cancer Using <i>Epirubicin</i> , <i>Oxaliplatin</i> and Infusional <i>Fluorouracil</i>	GIGAVEOF	Class I

CANCER DRUG MANUAL

REVISED MONOGRAPHS AND PATIENT HANDOUTS

Highlights of key changes and/or updates to the Monographs and Patient Handouts are listed below:

Capecitabine Patient Handout

- revised bullet with instructions for missed doses

Dabrafenib Monograph

- *Cautions and Side Effects*: added new information about kidney failure

Trametinib Monograph and Patient Handout

- *Cautions and Side Effects*: added new information about colitis, gastrointestinal perforation, and hemorrhage
- *Handout*: added bleeding problems, stroke, and abdominal pain to bullets in Get Emergency Help section

Vemurafenib Monograph and Patient Handout

- *Cautions and Side Effects*: added new information about acute kidney injury
- *Handout*: added kidney problems to See Your Doctor section

CHANGES IN EDITORIAL BOARD

The **Cancer Drug Manual writing team** and **Editorial Board** would like to welcome new team member **Dr. Anne Dar Santos, Provincial Drug Information Specialist** and new board member **Terri Gray, RN** (BCCA Centre for the North) to the CDM Editorial Board. Welcome Anne and Terri!

LIST OF NEW AND REVISED PROTOCOLS, PRE-PRINTED ORDERS AND PATIENT HANDOUTS

BC Cancer Agency Protocol Summaries, Provincial Pre-Printed Orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below. Protocol codes for treatment requiring BCCA Compassionate Access Program approval are prefixed with the letter “U”.

NEW PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)				
CODE	Protocol	PPPO	Patient Handout	Protocol Title
GIGAVEOCAP	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Palliative Therapy for Metastatic or Locally Advanced Gastric or Esophagogastric Cancer Using Epirubicin, Oxaliplatin and Capecitabine
GIGAVEOF	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Palliative Therapy for Metastatic or Locally Advanced Gastric or Esophagogastric Cancer Using Epirubicin, Oxaliplatin and Infusional Fluorouracil

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)					
CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
BRAVGEMT	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Contact physician clarified	Palliative Therapy for Metastatic Breast Cancer using Gemcitabine and PAclitaxel
UGIAJRALOX	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Drug administration and Precautions updated, minor typo corrected	Adjuvant Combination Chemotherapy for Node Positive Colon Cancer Using Oxaliplatin and Raltitrexed in Patients Intolerant to Fluorouracil or Capecitabine
GIAVPG	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Carboplatin option added, Precautions updated	First-line Palliative Chemotherapy for Advanced Gallbladder Cancer and Cholangiocarcinoma using Gemcitabine and CISplatin
GIGAJCPRT	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Tests and patient instructions for missing dose clarified	Adjuvant Chemotherapy of Gastric Cancer patients with Completely Resected Gastric Cancer using CISplatin and Capecitabine and Radiation Therapy
GIPAJGCAP	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Emetogenicity and dose modifications clarified	Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma Using Capecitabine and Gemcitabine
GIPAJGEM	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Precautions updated	Adjuvant Chemotherapy for Pancreatic Adenocarcinoma Using Gemcitabine
GIPGEM	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Precautions updated	Palliative Chemotherapy for Pancreatic Adenocarcinoma, Gallbladder Cancer, and Cholangiocarcinoma Using Gemcitabine
GIPGEMABR	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Tests clarified, Precautions updated	First Line Treatment of Locally Advanced and Metastatic Pancreatic Cancer with PAclitaxel-Nab (ABRAXANE®) and Gemcitabine
GOCXCATB	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Eligibility expanded, title revised	<u>Primary</u> Treatment of Metastatic or Recurrent Cancer of the Cervix with Bevacizumab, CARBOplatin and PAclitaxel
ULYBRENTUX	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Eligibility and references revised	Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma with Brentuximab Vedotin
LYCVP	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Contact physician updated	Treatment of Advanced Indolent Lymphoma using Cyclophosphamide, vinCRISTine, predniSONE
USMAVFIPI	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Minor typo corrected	First-Line Treatment of Unresectable or Metastatic Melanoma Using Ipilimumab

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
USMAVIPI	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Minor typo corrected	Treatment of Unresectable or Metastatic Melanoma Using Ipilimumab
USMAVNIV	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Minor typo corrected	Treatment of Unresectable or Metastatic Melanoma Using Nivolumab
SMAVTMZ	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Contact physician updated	Palliative Therapy for Malignant Melanoma with Brain Metastases Using Temozolomide
SMCCNU	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Contact physician updated	Palliative Therapy for Metastatic Melanoma Using Lomustine (CCNU)
SMTAM	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Contact physician updated	Palliative Therapy for Malignant Melanoma Using Tamoxifen

WEBSITE RESOURCES AND CONTACT INFORMATION

WEBSITE RESOURCES	WWW.BCCANCER.BC.CA
Systemic Therapy Update	www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy/systemic-therapy-update
Reimbursement & Forms: Benefit Drug List, Compassionate Access Program	www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy
Cancer Drug Manual	www.bccancer.bc.ca/health-professionals/professional-resources/cancer-drug-manual
Cancer Management Guidelines	www.bccancer.bc.ca/health-professionals/professional-resources/cancer-management-guidelines
Cancer Chemotherapy Protocols, Pre-Printed Orders, Protocol Patient Handouts	www.bccancer.bc.ca/health-professionals/professional-resources/chemotherapy-protocols
Systemic Therapy Program Policies	www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy
CON Pharmacy Educators	www.bccancer.bc.ca/health-professionals/professional-resources/pharmacy

CONTACT INFORMATION	PHONE	FAX	EMAIL
Systemic Therapy Update Editor			bulletin@bccancer.bc.ca
Provincial Systemic Therapy Program	604-877-6000 x 672247		mclin@bccancer.bc.ca
To update contact information of any CON sites, please contact:			
Oncology Drug Information	604-877-6275		druginfo@bccancer.bc.ca
Education Resource Nurse	604-877-6000 x 672638		nursinged@bccancer.bc.ca
Library/Cancer Information	604-675-8003 Toll Free 888-675-8001 x 8003		requests@bccancer.bc.ca
Pharmacy Professional Practice	604-877-6000 x 672247		mclin@bccancer.bc.ca
Nursing Professional Practice	604-877-6000 x 672623		ilundie@bccancer.bc.ca
OSCAR	888-355-0355	604-708-2051	oscar@bccancer.bc.ca
Compassionate Access Program (CAP)	604-877-6277	604-708-2026	cap_bcca@bccancer.bc.ca
Pharmacy Chemotherapy Certification	250-712-3900 x 686741		rxchemocert@bccancer.bc.ca
BCCA-Abbotsford Centre	604-851-4710 Toll Free 877-547-3777		
BCCA-Centre for the North	250-645-7300 Toll Free 888-775-7300		
BCCA-Fraser Valley Centre	604-930-2098 Toll Free 800-523-2885		
BCCA-Sindi Ahluwalia Hawkins Centre for the Southern Interior	250-712-3900 Toll Free 888-563-7773		
BCCA-Vancouver Centre	604-877-6000 Toll Free 800-663-3333		
BCCA-Vancouver Island Centre	250-519-5500 Toll Free 800-670-3322		

EDITORIAL REVIEW BOARD

Mario de Lemos, PharmD, MSc (Oncol) (Acting Editor)
Caroline Lohrisch, MD
Robert Crisp, BScPT, MBA

Lorraine Leitz, MLS
Jagbir Kaur, RN, MN
Rob Watt, BSc(Pharm)